

POSTER PRESENTATION

Open Access

Heart T2* for prediction of cardiac complications in well-treated thalassemia major patients

Alessia Pepe^{1*}, Antonella Meloni¹, Giuseppe Rossi², Petra Keilberg¹, Cristina Salvatori¹, Elisabetta Chiodi³, Claudio Ascioti⁴, Antonella Carollo⁵, Vincenzo Positano¹, Massimo Lombardi¹

From 15th Annual SCMR Scientific Sessions
Orlando, FL, USA. 2-5 February 2012

Background

T2* Magnetic Resonance Imaging (MRI) technique allows noninvasive quantification of organ-specific iron burden, playing a key role in the management of thalassemia major (TM) patients. There are few data on the incidence of heart failure and arrhythmias in TM patients according to baseline T2* values. So, the aim of this study was to establish prospectively the risk of cardiac complications in a large cohort of well-treated TM patients.

Methods

We considered 527 TM patients (252 males, mean age 30±9) for who clinical data relative to a period of 5 years after the first MRI were collected in a central data base. At time of the first scan mean ferritin levels were 1653±1559 ng/l, global heart was 27±13 ms, and

excellent/good level of compliance were present in the 96% of the study population.

Results

At 5 years of follow-up, we recorded 24 cardiac events: 4 episodes of cardiac failure, 15 of arrhythmia, 1 of pulmonary hypertension and 4 of other cardiac complications. The majority of these events (21/24) happened within the first 24 months subsequent to the MRI, so we considered this follow-up period.

At the first MRI scan, in patients with cardiac complications the global heart T2* was 22.5 ±12.4 ms. In comparison with global heart T2* values ≥20 ms, there was not a significantly increased risk of cardiac complications associated with global heart T2* values <20 ms (HR= 2.028 P=0.09).




Figure 1

¹CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy
Full list of author information is available at the end of the article

In the heart failure patients the global heart T2* was 19 ± 12 ms. In comparison with global heart T2* values ≥ 20 ms, there was not a significantly increased risk of heart failure associated with global heart T2* values < 20 ms (HR=1.9 P=0.524) or < 10 ms (HR=2.6 P=0.443).

In the arrhythmic patients the global heart T2* was 25 ± 13 ms. In comparison with global heart T2* values ≥ 20 ms, there was not a significantly increased risk of arrhythmia associated with global heart T2* values < 20 ms (HR=2.1 P=0.179) or < 10 ms (HR=0.8 P=0.824).

During the follow up changes in the chelation therapy (type and/or dose-frequencies) were found in $> 25\%$ of the study population.

Conclusions

We detected very few cardiac events, almost all concentrated in the first 24 months. In a large cohort of well-treated TM patients heart T2* lost its power in predicting cardiac events probably due to a patient-specific adjustment of the chelation therapy MRI-guided.

Funding

“No-profit” support by industrial sponsorships (Chiesi, Apotex and GE Healthcare) and “Ministero della Salute, fondi ex art. 12 D.Lgs. 502/92 e s.m.i., ricerca sanitaria finalizzata anno 2006” e “Fondazione L. Giambrone”.

Author details

¹CMR Unit, Fondazione G.Monasterio CNR-Regione Toscana and Institute of Clinical Physiology, Pisa, Italy. ²Epidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy. ³Dipartimento di Radiologia, Ospedale “Sant’Anna”, Ferrara, Italy. ⁴Struttura Complessa di Cardioradiologia-UTIC, P.O. “Giovanni Paolo II”, Lamezia Terme, Italy. ⁵Servizio Talassemia-U.O. Pediatria Talassemia, Az. Osp. “Sant’Antonio abate”, Trapani, Italy.

Published: 1 February 2012

doi:10.1186/1532-429X-14-S1-P195

Cite this article as: Pepe et al.: Heart T2* for prediction of cardiac complications in well-treated thalassemia major patients. *Journal of Cardiovascular Magnetic Resonance* 2012 **14**(Suppl 1):P195.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

